Announcements
- Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference
- Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
- Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update
- Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024
- Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress
- Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder
- Liquidia Corporation Announces Updates to Operations Leadership
- Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims
- Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD
- Liquidia Corporation Announces $100 Million in New Financings
More ▼
Key statistics
On Friday, Liquidia Corp (LT4:DUS) closed at 11.78, 9.07% above its post-IPO low of 10.80, set on Apr 29, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.00 |
---|---|
High | 12.00 |
Low | 11.78 |
Bid | 11.75 |
Offer | 12.01 |
Previous close | 12.03 |
Average volume | 438.70 |
---|---|
Shares outstanding | 76.03m |
Free float | 66.60m |
P/E (TTM) | -- |
Market cap | 972.40m USD |
EPS (TTM) | -1.21 USD |
Data delayed at least 15 minutes, as of May 03 2024 18:30 BST.
More ▼